uniQure Announces Management Changes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

uniQure Announces Management Changes



uniQure, a human gene therapy company, reported the appointment of Eric Goossens as its new COO. Goossens has 15 years of experience in management and leadership for technology-based companies, including the biopharmaceutical industry.

In addition, uniQure appointed Deya Corzo, MD, as vice president, Medical Affairs for the US as of April 1, 2014. Goossens joins uniQure from Dätwyler Pharma Packaging Belgium N.V where he was site director for three years. Corzo previously worked at Celgene, as executive director, Medical Affairs/Oncology from 2012 to 2014.

Source: uniQure

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here